肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

肿瘤标志物HE4中国人群参考值研究结果发布

2014-11-26 MedSci MedSci原创

HE4肿瘤标志物参考值
关注

人附睾蛋白4（human epididymis protein 4,HE4）作为一种新的肿瘤标志物，在良性疾病患者和正常人血清中含量极低，而在卵巢癌组织和患者血清中均高度表达。在日前上海举行的“血清肿瘤标志物在卵巢癌诊疗中的临床应用”研讨会上，解放军总医院田亚平教授首次公布了HE4中国人群参考值大型临床研究的结果。这一历时两年的多中心、大样本的临床研究，由解放军总医院、天津市肿瘤医院等9家医院联合

人附睾蛋白4（human epididymis protein 4,HE4）作为一种新的肿瘤标志物，在良性疾病患者和正常人血清中含量极低，而在卵巢癌组织和患者血清中均高度表达。在日前上海举行的“血清肿瘤标志物在卵巢癌诊疗中的临床应用”研讨会上，解放军总医院田亚平教授首次公布了HE4中国人群参考值大型临床研究的结果。

这一历时两年的多中心、大样本的临床研究，由解放军总医院、天津市肿瘤医院等9家医院联合开展，样本量超过2300例、覆盖了18～95岁的女性，旨在建立中国人群HE4水平的参考值范围，研究HE4对卵巢癌诊断的敏感性和特异性，以更好地指导Elecsys HE4检测结果的临床应用。

研究表明，目前中国表观健康女性HE4为105.10pmol/L且随年龄增长呈递增趋势，绝经后妇女较绝经前HE4水平有显著升高。田亚平表示，该研究为卵巢癌的诊断及筛查提供了大样本的中国健康人群的参考值；HE4联合糖链多肽抗原125（CA125）可将早期卵巢癌诊断的敏感度提高到92%；HE4检测有助卵巢癌的早期诊断、疾病复发和转移的风险评估及随访监测，显著提高患者生存率。

MedSci评：HE4作为一种潜在的新型肿瘤标志物，近年来在国际上引起广泛的重视。主要用于卵巢癌，非小细胞肺癌等肿瘤的鉴别诊断。相关文献如下：

Wang X, Fan Y, Wang J, Wang H, Liu W.Evaluating the expression and diagnostic value of human epididymis protein 4 (HE4) in small cell lung cancer.Tumour Biol. 2014 Jul;35(7):6847-53.

Zhen S, Bian LH, Chang LL, Gao X.Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis.Mol Clin Oncol. 2014 Jul;2(4):559-566

Bie Y, Zhang Z.Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis.World J Surg Oncol. 2014 May 29;12:169.

Wang J, Gao J, Yao H, Wu Z, Wang M, Qi J.Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis.Tumour Biol. 2014 Jun;35(6):6127-38

Chen WT, Gao X, Han XD, Zheng H, Guo L, Lu RQ.HE4 as a serum biomarker for ROMA prediction and prognosis of epithelial ovarian cancer.Asian Pac J Cancer Prev. 2014;15(1):101-5

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1746929, encodeId=44e11e46929ea, content=<a href='/topic/show?id=2103862699' target=_blank style='color:#2F92EE;'>#HE4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8626, encryptionId=2103862699, topicName=HE4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53a535877307, createdName=cqlidoudou, createdTime=Mon Jan 05 15:13:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739413, encodeId=cc311e394130a, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Wed Jan 28 06:13:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840826, encodeId=7b64184082639, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jan 20 16:13:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17713, encodeId=766d1e71309, content=正需要这方面文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=127f1616391, createdName=happypig, createdTime=Thu Mar 05 15:29:00 CST 2015, time=2015-03-05, status=1, ipAttribution=)]
    2015-01-05 cqlidoudou

    #HE4#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1746929, encodeId=44e11e46929ea, content=<a href='/topic/show?id=2103862699' target=_blank style='color:#2F92EE;'>#HE4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8626, encryptionId=2103862699, topicName=HE4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53a535877307, createdName=cqlidoudou, createdTime=Mon Jan 05 15:13:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739413, encodeId=cc311e394130a, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Wed Jan 28 06:13:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840826, encodeId=7b64184082639, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jan 20 16:13:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17713, encodeId=766d1e71309, content=正需要这方面文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=127f1616391, createdName=happypig, createdTime=Thu Mar 05 15:29:00 CST 2015, time=2015-03-05, status=1, ipAttribution=)]
    2015-01-28 1249894fm84暂无昵称

    #研究结果#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1746929, encodeId=44e11e46929ea, content=<a href='/topic/show?id=2103862699' target=_blank style='color:#2F92EE;'>#HE4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8626, encryptionId=2103862699, topicName=HE4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53a535877307, createdName=cqlidoudou, createdTime=Mon Jan 05 15:13:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739413, encodeId=cc311e394130a, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Wed Jan 28 06:13:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840826, encodeId=7b64184082639, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jan 20 16:13:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17713, encodeId=766d1e71309, content=正需要这方面文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=127f1616391, createdName=happypig, createdTime=Thu Mar 05 15:29:00 CST 2015, time=2015-03-05, status=1, ipAttribution=)]
    2015-01-20 一叶知秋

    #标志物#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1746929, encodeId=44e11e46929ea, content=<a href='/topic/show?id=2103862699' target=_blank style='color:#2F92EE;'>#HE4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8626, encryptionId=2103862699, topicName=HE4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53a535877307, createdName=cqlidoudou, createdTime=Mon Jan 05 15:13:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739413, encodeId=cc311e394130a, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Wed Jan 28 06:13:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840826, encodeId=7b64184082639, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jan 20 16:13:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17713, encodeId=766d1e71309, content=正需要这方面文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=127f1616391, createdName=happypig, createdTime=Thu Mar 05 15:29:00 CST 2015, time=2015-03-05, status=1, ipAttribution=)]
    2015-03-05 happypig

    正需要这方面文章

    0

相关资讯

大样本卵巢癌肿瘤标志物研究启动

　　10月27日，解放军总医院、天津市肿瘤医院等9家大型三甲医院及肿瘤专科医院联合罗氏诊断，在京启动人附睾蛋白4（HE4）多中心、大样本临床研究。 　　据悉，HE4是一种与卵巢癌有关的新型肿瘤标志物，88%的卵巢癌患者都会出现HE4升高，因此HE4适用于卵巢癌的早期检测、鉴别诊断、治疗监测及预后评估。解放军总医院教授田亚平介绍说，国家食品药品监督管理局已批准国际先进的卵巢癌Elecsys HE4

Obstet Gynecol：FDA明确卵巢癌生物标志物测试HE4

美国食品与药品管理局FDA明确卵巢癌生物标志物测试，FDA的批准扫清了此工具全国范围内使用的道路，这个工具在估计具有骨盆腔肿块女性的卵巢癌风险性方面表现出极大特异性。 FDA已批准卵巢恶性肿瘤风险计算法（ROMA）联合蛋白HE4和CA125血液测试的销售和使用。研究表明，用ROMA计算法检测HE4和CA125水平在测定绝经前和绝经后女性卵巢癌风险性上显示出高度精确性。 血液测试与ROMA计

CA125及HE4联合检测可用于中国妇女盆腔肿块的罹患卵巢癌风险

  雅培ARCHITECT ROMA（卵巢恶性肿瘤风险评估法则）-“CA125及HE4”联合检测，在术前评估存在盆腔肿块的中国妇女罹患卵巢癌风险，准确性可接近90%。    卵巢癌是女性生殖器官常见的肿瘤之一，发病率仅次于子宫颈癌和子宫体癌列居 第三位。但因其早期缺乏特异性症状以及缺乏有效的筛查手段，70%的病人在首次就诊时已是晚期，治疗大难度、复发率高，5